GvHD is a medical complication following the receipt of transplanted tissue from a genetically different person.
Cynata has selected five leading NHS hospitals in England to participate in this clinical trial, which involves its lead Cymerus™ mesenchymal stem cell (MSC) product, CYP-001.
The company had already received authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC).
Hence, all approvals required prior to the commencement of patient recruitment at NHS centres are now in place.
Cynata is now working on initiating these centres and getting recruitment underway as soon as possible.
Last month, the company filed a patent application describing certain novel aspects of its proprietary Cymerus™ therapeutic mesenchymal stem cell technology.
Should the application mature to a granted patent, it will provide valuable commercial exclusivity in key markets around the world.
Cynata’s share price has increased by 76% since the beginning of 2016, last trading at $0.625.